ASLAN Pharmaceuticals Limited (ASLN) |
|
4.195 0.005 (0.12%)
|
06-06 15:15 |
|
Open: |
4.09 |
Pre. Close: |
4.19 |
|
High:
|
4.195 |
Low:
|
4.02 |
|
Volume:
|
80,433 |
Market Cap:
|
69(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 3:17:23 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 4.98 One year: 5.47 |
| Support: |
Support1: 3.58 Support2: 2.98 |
| Resistance: |
Resistance1: 4.26 Resistance2: 4.69 |
| Pivot: |
4.1 |
| Moving Average: |
MA(5): 4.13  MA(20): 4.18
MA(100): 3.63 MA(250): 3.11 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 55.5 %D(3): 53.1 |
| RSI: |
RSI(14): 52.2 |
| 52-week: |
High: 4.94 Low: 1.7 |
| Average Vol(K): |
3-Month: 53 (K) 10-Days: 95 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ASLN ] has closed below upper band by 48.9%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.26 - 4.29 |
4.29 - 4.31 |
|
Low:
|
4 - 4.02 |
4.02 - 4.05 |
|
Close:
|
4.11 - 4.15 |
4.15 - 4.19 |
|
Company Description |
|
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore. |
Headline News |
Thu, 01 Jun 2023
2023-06-01 | NDAQ:ASLN | Press Release | ASLAN ... - Stockhouse Publishing
Wed, 31 May 2023
Roth MKM Initiates Coverage of ASLAN Pharmaceuticals Ltd - ADR ... - Nasdaq
Thu, 18 May 2023
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of ... - BioSpace
Sat, 29 Apr 2023
HC Wainwright & Co. Maintains ASLAN Pharmaceuticals Ltd - ADR ... - Nasdaq
Tue, 28 Mar 2023
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing ... - GlobeNewswire
Mon, 13 Mar 2023
Hedge funds owners may take dramatic actions as ASLAN Pharmaceuticals Limited's (NASDAQ:ASLN) recent 25% drop adds to one-year losses - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
16 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
25.2 (%) |
|
Shares Short
|
484 (K) |
|
Shares Short P.Month
|
408 (K) |
Stock Financials |
|
EPS
|
-4.2 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.67 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-44.8 |
|
Return on Equity (ttm)
|
-209.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.31 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.98 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
6.13 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
